Subscribe
  
IPQ Inside the global regulatory dialogue

IQ Consortium Creates Foundation to Address Pharma Lab Data Disconnects as Momentum Builds in Second Year

Jul 9th, 2012

Please Log in to print the full article

The International Consortium on Innovation and Quality in Pharmaceutical Development (IQ Consortium) is putting in place a separate foundation to focus on developing a common format for generating, storing, retrieving, transmitting, analyzing and archiving pharmaceutical analytical lab data and the reports generated from that data.

Attacking the problem of the inefficiencies and limitations created by the current disconnects between the pharma labs and the inability to interlink the information that they are generating has been high on the IQ Consortium’s priority list.

The magnitude of the challenges involved has prompted the consortium to establish a sister organization dedicated to addressing them.

The goal of the newly established “Foundation for Laboratory Data Standards” (FLDS) is to create an “interoperable open-source laboratory information framework” that will provide significant industry-wide financial and innovative technical benefits in the lab data and information management arena.

The problems FLDS will focus on derive from the fact that data generated in laboratories across the industry by various types of analytical instruments have no common standard for file formats or database structures.

The absence of a common format, IQ stresses in its proposal to form FLDS, impedes data exchange, data archiving, data re-analysis, custom data analysis, and data conversion from older to newer versions of software, or between different software applications.

The lack of standardization, the proposal notes, also leads to “critically important” documents, such as stability reports, certificates of analysis, and regulatory submissions, “that are derived from multiple sources of raw laboratory data and are costly to create.”  These costs impact operations within a company’s labs, between partnering companies, and between a company and contract research organizations (CROs).

Obstacles for data exchange also contribute to “missed opportunity” costs because they make it difficult to collaborate and innovate.

[The story continues for subscribers beginning on page 2, and includes the history of the IQ Consortium, work done to date, and the perspective of an Abbott VP on why the consortium is critical to moving the pharma industry forward.  Nonsubscribers can purchase the story for $195 by contacting Wayne Rhodes (wrhodes@IPQpubs.com).  For subscription/license information, click here.]

See related stories:

Vertex Harnesses QbD to Solve Difficult Formulation and Manufacturing Issues

Biopharm Modeling and Continuous Manufacturing Will Help Drive Vertex’ Drug Development and QbD

Virtual Innovator Vertex Pioneers New QbD Course with CMO Partners

Pages: 1 2
  • Share/Bookmark

©2014 IPQ Publications